Oculis Set to Showcase Breakthrough Therapies at Major Conferences
Oculis Unveils New Therapies at Leading Ophthalmology Events
Oculis Holding AG (NASDAQ: OCS / ICX: OCS.IC), a global biopharmaceutical company dedicated to addressing significant unmet needs in ophthalmic and neuro-ophthalmic diseases, is set to present its innovative late-stage pipeline at several key ophthalmology conferences. With presentations confirmed for Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, and the Retina World Congress (RWC), Oculis aims to share advancements that could greatly impact the treatment landscape.
Key Highlights of the Presentations
The presentations will feature crucial insights from the DME AWARE Delphi Study, specifically focusing on unmet needs in diabetic macular edema (DME) patient management. Esteemed experts will share the interim results that underline areas for improvement. Oculis will also showcase data from the Phase 3 DIAMOND program concerning OCS-01 eye drops, which are being developed as the first non-invasive treatment option for DME. This innovative approach responds to unmet needs related to early treatments and inadequate responses to existing standards of care.
Moreover, insights from the Phase 2b RELIEF trial examining Licaminlimab (OCS-02) in dry eye disease (DED) will be discussed. This study has yielded promising results, emphasizing the potential for genetic biomarkers to direct personalized treatment strategies for DED patients. Licaminlimab represents a transformative step in treating this condition, which has long been characterized by trial-and-error approaches.
Conference Presentation Details
Specific details about each presentation include:
Eyecelerator 2025
Presentation Title: Company showcases – Retina: TKI and Drug Delivery
Presenter: Sharon Klier, M.D., Chief Development Officer
Date/Time: Friday, May 2, 2025, 1:30 PM – 3:00 PM MST
ARVO Annual Meeting 2025
Presentation Titles:
Interim results of the DME AWARE Delphi Study
Presenter: Anat Loewenstein, M.D.
Date/Time: Monday, May 5, 2025, 3:00 PM – 4:45 PM MST
BCVA and CST Improvement with OCS-01 Eye Drops in DME
Presenter: Carl Danzig, M.D.
Date/Time: Wednesday, May 7, 2025, 10:15 AM – 12:00 PM MST
Licaminlimab in treating dry eye disease
Presenter: Anat Galor, M.D.
Date/Time: Thursday, May 8, 2025, 8:00 AM – 9:45 AM MST
Retina World Congress 2025
Presentation Titles:
Wet AMD, DR, RVO – Part 2, Panel Discussion
Participant: Riad Sherif, M.D., Chief Executive Officer
Date/Time: Thursday, May 8, 2025, 11:25 AM – 11:59 AM ET
BCVA and CST Improvement with OCS-01 Eye Drops
Presenter: David Almeida, M.D.
Date/Time: Thursday, May 8, 2025, 6:08 PM – 6:13 PM ET
The Experts Behind the Innovations
Anat Loewenstein, M.D., MHA, a leading authority in retina and ophthalmology, will share insights into patient management strategies during the presentations. Her extensive background and numerous scholarly contributions make her a crucial figure in the advancements of DME care.
Additionally, Carl Danzig, M.D., and Anat Galor, M.D., bring their expertise in retinal diseases and dry eye treatment to the forefront, emphasizing research and new therapeutic applications that can better serve patients.
David Almeida, M.D., M.BA., Ph.D., FRCSC, DABO, will further expand on the clinical landscape with valuable data stemming from his participation in significant trials, thus adding another layer to Oculis’ commitment to innovative treatment solutions.
About Oculis and Its Innovative Pipeline
Oculis focuses on creating innovative treatment options for eye diseases that heavily impact quality of life. The company’s pipeline includes OCS-01, an eye drop candidate specifically for diabetic macular edema (DME), and Licaminlimab (OCS-02), aimed at treating dry eye disease (DED). With a robust research and development strategy, Oculis is set to revolutionize how these conditions are managed, prioritizing non-invasive solutions and personalized medicine.
For those seeking further information about Oculis' initiatives and presentations at upcoming conferences, you can visit www.oculis.com.
Frequently Asked Questions
What is Oculis focused on at these conferences?
Oculis is highlighting its innovative late-stage pipeline, focusing on treatments for diabetic macular edema (DME) and dry eye disease (DED).
When will Oculis present its findings?
Oculis will present at Eyecelerator 2025, ARVO Annual Meeting, and the Retina World Congress in early May 2025.
Who are the key presenters at Oculis' sessions?
Notable presenters include Dr. Anat Loewenstein, Dr. Carl Danzig, Dr. Anat Galor, and Dr. David Almeida, each bringing significant expertise in ophthalmology.
What is the significance of the OCS-01 eye drops?
OCS-01 aims to be the first non-invasive treatment option for DME, offering an alternative to current invasive therapies.
How does Licaminlimab aim to transform DED treatment?
Licaminlimab is designed to utilize genetic biomarkers for personalized treatment, turning a traditionally trial-driven process into a more targeted approach.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.